Top

Published in:

01-08-2011 | Research Article

⁶⁸Ga-DOTA-TATE PET vs. ¹²³I-MIBG in Identifying Malignant Neural Crest Tumours

Authors: Meeran Naji, Chunlei Zhao, Sarah J. Welsh, Richard Meades, Zarni Win, Annalisa Ferrarese, Tricia Tan, Domenico Rubello, Adil Al-Nahhas

Published in: Molecular Imaging and Biology | Issue 4/2011

Abstract

Purpose

We aimed to compare imaging with ¹²³I-MIBG and ⁶⁸Ga-DOTA-TATE in neural crest tumours (NCT) to see if the latter could offer more advantage in detecting extra lesions and have higher sensitivity for malignant lesions.

Procedures

We retrospectively reviewed 12 patients (M = 10, F = 2; age range 20–71 years) with NCT (phaeochromocytomas = 7, paragangliomas = 4, medullary thyroid cancer = 1) who underwent both ⁶⁸Ga-DOTA-TATE positron emission tomography (PET) or PET/computed tomography (CT) and ¹²³I-MIBG single-photon emission computed tomography within 6 months. Visual assessment of all lesions and measurement of target/non-target (T/N) ratio in selected lesions were performed. Five patients (aged 50 or less) had SDHB screening results correlated with imaging results of both radiopharmaceuticals. All patients had contrast-enhanced CT and/or other cross-sectional imaging.

Results

⁶⁸Ga-DOTA-TATE PET showed tumour lesions in ten out of 12 patients with confirmed disease, while ¹²³I-MIBG showed lesions in five out of 12 patients. In one patient, both ⁶⁸Ga-DOTA-TATE PET and ¹²³I-MIBG were negative, but CT, magnetic resonance imaging, and 2-deoxy-2-[¹⁸F]fluoro-D-glucose PET scans identified a lesion in the thorax. ⁶⁸Ga-DOTA-TATE and ¹²³I-MIBG detected a total of 30 lesions, of which 29/30 were positive with ⁶⁸Ga-DOTA-TATE and 7/30 with ¹²³I-MIBG. We also found higher incidence of SDHB positive results in patients with positive ⁶⁸Ga-DOTA-TATE.

Conclusion

Our limited data suggest that ⁶⁸Ga-DOTA-TATE is a better imaging agent for NCT and detects significantly more lesions with higher T/N ratio compared to ¹²³I-MIBG. ⁶⁸Ga-DOTA-TATE was more likely to detect malignant lesions as indicated by correlating imaging results with SDHB screening.

Neumann HP, Bausch B, McWhinny SR, Bender BU, Gimm O, Franke G et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466PubMedCrossRef

O’Riordain D, Young WF, Grant CS, Carney JA, van Heerden (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20:916–922PubMedCrossRef

Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 24:2331–2339PubMedCrossRef

Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P (2007) 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 28:359–363PubMedCrossRef

Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I et al (2008) Comparison of 6-18F-fluorodopamine positron emission tomography to 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma. J Nucl Med 49:1613–1619PubMedCrossRef

Lewigton VJ (2003) Targeted radionuclide therapy for neuroendocrine tumours. Endocr-Relat Cancer 10:497–501CrossRef

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S–66SPubMed

Smith SL, Vincent RM, Perkins AC, Wastie ML, Sokal M (2001) Does simple estimation of ¹³¹I-metaiodobenzylguanidine uptake in patients with neural crest tumours correlate with clinical outcome? Nucl Med Commun 22:257–260PubMedCrossRef

Pasini B, Stratakis CA (2009) SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266(1):19–42PubMedCrossRef

10.

Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Léger C et al (2003) Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299:700–704PubMedCrossRef

11.

Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54PubMedCrossRef

12.

Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–851PubMedCrossRef

13.

Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268–270PubMedCrossRef

14.

Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F (2007) Pheochromocytoma: an update on genetics and management. Endocr-Relat Cancer 14:935–956PubMedCrossRef

15.

Benn DE, Gimenez-Roqueplo A-P, Reilly JR, Bertherat J, Burgess J, Byth K et al (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:27–836

16.

Klein RD, Jin L, Rumilla K, Young WF Jr, Lloyd RV (2008) Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol 17(2):94–100PubMedCrossRef

17.

Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95(16):1196–1204PubMedCrossRef

18.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr-Relat Cancer 14(3):569–585PubMedCrossRef

19.

Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479–491PubMedCrossRef

20.

Go AS (1998) Refining probability: an introduction to the use of diagnostic tests. In: Friedland DJ (ed) Evidence-based medicine. McGraw-Hill, New York, pp 12–33

21.

Wieland DM, Wu JL, Brown LE (1980) Radiolabelled adrenergic neuron blocking agents: adrenomedullary imaging with 131Iiodobenzylguanidine. J Nucl Med 21:349–353PubMed

22.

Beierwaltes WH (1991) Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors. Part II. J Nucl Med 32:1627–1639PubMed

23.

McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM (1985) Radioiodobezylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132–153PubMedCrossRef

24.

Shulkin BL, Ilias I, Sisson JC, Pacak K (2006) Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci 1073:374–382PubMedCrossRef

25.

Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE et al (2006) 11C-metahydroxyephedrine and 18F-fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected phaeochromocytoma. Ann Surg Oncol 13(2):187–197PubMedCrossRef

26.

Reynolds S, Lewington V (2008) Radionuclide imaging of phaeochromocytoma and paraganglioma. Imaging 34:21–24

27.

Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albersy F, Dullaart RPF (2008) ¹¹¹In-octreotide is superior to ¹²³I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232–1237PubMedCrossRef

28.

Ilias I, Pacak K (2008) A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 35(Suppl 1):S27–S34PubMedCrossRef

29.

Brink I, Hoegerle S, Klisch J, Bley TA (2005) Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4(1):61–68PubMedCrossRef

30.

Maurea S, Mainolfi C, Wang H, Varrella P, Panico MR, Klain M et al (1996) Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions. Radiol Med 92:782–787PubMed

31.

Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC (1999) Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35–41PubMed

32.

Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT (1996) Malignant phaeochromocytoma of the anterior mediastinum: PET findings with [18F] FDG and 82Rb. J Comput Assist Tomogr 20:312–316PubMedCrossRef

33.

Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I et al (2006) Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 27:31–36PubMedCrossRef

34.

Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B et al (2009) Comparison of 18F-fluoro-L-DOPA, ¹⁸F-fluoro-deoxyglucose, and ¹⁸F-fluorodopamine PET and ¹²³I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94(12):4757–4767PubMedCrossRef

35.

Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A (2008) PET imaging in endocrine tumours. Minerva Endocrinol 33(2):41–52PubMed

36.

Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D (2007) What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34(12):1897–1901PubMedCrossRef

Title: 68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours
Authors: Meeran Naji
Chunlei Zhao
Sarah J. Welsh
Richard Meades
Zarni Win
Annalisa Ferrarese
Tricia Tan
Domenico Rubello
Adil Al-Nahhas
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 4/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-010-0396-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Ga-DOTA-TATE PET vs. ¹²³I-MIBG in Identifying Malignant Neural Crest Tumours

Abstract

Purpose

Procedures

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2011

Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates

Erratum to: Chronic Cannabinoid Administration to Periadolescent Rats Modulates the Metabolic Response to Acute Cocaine in the Adult Brain

Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT

Isoflurane Anaesthesia Differentially Affects the Amphetamine Sensitivity of Agonist and Antagonist D2/D3 Positron Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine Release

Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET

Quantitation in Bioluminescence Imaging by Correction of Tissue Absorption for Experimental Oncology